BioSpace News Archive

ANYMEDI participated in AI showcase of RSNA 2019 (Radiological Society of North America), held in Chicago, U.S. from December 1st to 6th, exhibiting patient-specific surgical applications based on AI, 3D printing and AR/VR technologies.

A recent study by the National Institute for Occupational Health and Safety revealed that cancer is currently the leading cause of death among firefighters.

Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio” or the “Company”) announced today the appointment of Professor Michael Levitt of Stanford University to be the Chief Consultant of Anpac Bio’s Innovation and Technical Advisory Board.

Young Living, the world leader in essential oils, announced a new partnership with the Golden Einkorn Farm in Sault, located in the French region of Provence.

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, and Lipidor AB (Nasdaq First North: LIPI) (“Lipidor”), a Swedish topical drug development company, have today signed an agreement for the joint development of topical medical cannabis products commencing with evaluating the feasibility of incorporating active pharmaceutical ingredients

DTN, an independent source of insights, analysis and decision-support solutions, has acquired MetStat, an industry leader in precipitation analysis and analytics.

NCCN Patient Advocacy Summit examines the patient perspective on delivering value and high-quality care in order to promote more patient-centric cancer care and improve quality-of-life for people with cancer #NCCNPolicy

Tetra Tech, Inc. announced the U.S. Environmental Protection Agency’s Office of Science and Technology awarded Tetra Tech a $21 million, single-award contract to support the Agency’s mission in assessing and managing threats to ecological and human health.

Forty Seven, Inc., a clinical stage immuno-oncology company, announced that it has commenced an underwritten public offering of $140,000,000 of shares of its common stock.

Despite longstanding medical guidelines recommending biomarker testing for all patients with metastatic colon cancer, a new study published in JCO Precision Oncology shows that only 40 percent of patients are tested according to guidelines.